ReviewBMC endocrine disorders2025
Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?
Review in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Experimental models in diabetes research.Laboratory animal research · 2026Review
- Emerging roles of the long non-coding RNAs MALAT1 and TUG1 during differentiation of adipose tissue-derived mesenchymal stem cells towards insulin-producing cells.Stem cell research & therapy · 2026Article
- Review
- The rebirth of pancreas transplantation: an innovative, fully robotic, reproducible surgical technique.BMC surgery · 2026Review
- Evaluating iPSC-based interventions for diabetes: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes remains one of the significant health struggles worldwide, leading to disability and mortality. There are several types, with Types 1 and 2 representing the majority of cases. Pancreatic beta cells play a key role in glucose control through the secretion of insulin. Insulin, a key player, is under-secreted in diabetes due to autoimmune destruction of the beta cells in type 1 diabetes and exhaustion of beta cell secretion in type 2. Hence, insulin plays a central role in the management of both conditions. Lifestyle modifications and pharmacological agents are significant components of managing diabetes, although they come with limitations; hence, the exploration of stem cells in diabetes management. A thorough literature search was conducted across several databases, identifying randomized and non-randomized controlled trials that utilized stem cells in patients with diabetes. The intervention details, primary and secondary outcomes, key findings, and safety profiles were documented and discussed. We explored key protocols and methods for generating pancreatic beta-like cells from stem cells, as well as the role of specific molecules and pathways in stem cell differentiation. In this paper, we also discuss preclinical animal studies, explore the challenges of immunogenicity, and address ethical concerns that limit the implementation of stem cells in clinical practice. A comparative analysis was conducted to evaluate conventional insulin therapy, islet transplantation, and stem cell-based approaches. Although stem cells represent a potentially valuable direction, their application clinically remains mainly experimental, and future studies should incorporate larger cohorts, diverse populations with varying comorbidities, and extended follow-up periods to better ascertain their long-term efficacy and safety. CLINICAL TRIAL NUMBER: Not applicable
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.